应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
BIIB 渤健公司
未开盘 04-18 16:00:00 EDT
190.52
-1.64
-0.85%
盘后
190.52
+0.00
0.00%
19:59 EDT
最高
192.56
最低
189.52
成交量
151.20万
今开
191.75
昨收
192.16
日振幅
1.58%
总市值
276.94亿
流通市值
275.90亿
总股本
1.45亿
成交额
2.89亿
换手率
1.04%
流通股本
1.45亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
小摩:维持Biogen(BIIB.US)评级,由中性调整至中性评级, 目标价由270.00美元调整至240.00美元。
智通财经 · 04-11
小摩:维持Biogen(BIIB.US)评级,由中性调整至中性评级, 目标价由270.00美元调整至240.00美元。
美国研究综述-Airbnb、Albemarle、Biogen
Reuters · 04-11
美国研究综述-Airbnb、Albemarle、Biogen
BUZZ-百健因阿尔茨海默氏症皮下注射药物Leqembi申请延迟而下跌
Reuters · 04-01
BUZZ-百健因阿尔茨海默氏症皮下注射药物Leqembi申请延迟而下跌
更新版 1-欧盟药品监管机构未在会议记录中提及卫材-百健的阿尔茨海默氏症药物
Reuters · 03-22
更新版 1-欧盟药品监管机构未在会议记录中提及卫材-百健的阿尔茨海默氏症药物
BUZZ-美国食品及药物管理局推迟阿尔茨海默氏症药物决策后,礼来公司股价下跌
Reuters · 03-09
BUZZ-美国食品及药物管理局推迟阿尔茨海默氏症药物决策后,礼来公司股价下跌
BUZZ-礼来因美国食品及药物管理局推迟阿尔茨海默氏症药物决策而下跌
Reuters · 03-08
BUZZ-礼来因美国食品及药物管理局推迟阿尔茨海默氏症药物决策而下跌
美国 FDA 推迟礼来老年痴呆症药物决策,要求成立顾问小组
Reuters · 03-08
美国 FDA 推迟礼来老年痴呆症药物决策,要求成立顾问小组
日本卫材公司称美国引进阿尔茨海默氏症药物Leqembi的速度低于预期
Reuters · 03-07
日本卫材公司称美国引进阿尔茨海默氏症药物Leqembi的速度低于预期
欧盟药品监管机构支持百健公司的 ALS 药物
Reuters · 02-23
欧盟药品监管机构支持百健公司的 ALS 药物
渤健公司2023财年实现净利润11.61亿美元,同比减少61.90%
自选股智能写手 · 02-17
渤健公司2023财年实现净利润11.61亿美元,同比减少61.90%
BUZZ-Sage Therapeutics 因第四季度收入增长、亏损收窄而上涨
Reuters · 02-14
BUZZ-Sage Therapeutics 因第四季度收入增长、亏损收窄而上涨
百健公司收到司法部传票,内容涉及在国外的业务运营情况
Reuters · 02-14
百健公司收到司法部传票,内容涉及在国外的业务运营情况
美国研究综述-布鲁克公司、Cymabay Therapeutics、SSR 矿业公司
Reuters · 02-14
美国研究综述-布鲁克公司、Cymabay Therapeutics、SSR 矿业公司
《美股业绩》渤健药厂(BIIB.US)业绩预测逊预期 股价挫逾7%
阿斯达克财经 · 02-14
《美股业绩》渤健药厂(BIIB.US)业绩预测逊预期 股价挫逾7%
嗡嗡声--美国股票走势-捷蓝航空公司、LPL Financial、Nvidia
Reuters · 02-14
嗡嗡声--美国股票走势-捷蓝航空公司、LPL Financial、Nvidia
BUZZ-利润和营收不及预期,百健公司技术面转为看跌
Reuters · 02-14
BUZZ-利润和营收不及预期,百健公司技术面转为看跌
BUZZ-第四季度利润和收入不及预期,百健公司下跌
Reuters · 02-14
BUZZ-第四季度利润和收入不及预期,百健公司下跌
百健Q4销售低于预期,阿尔兹海默症药物短期内难创收
智通财经 · 02-13
百健Q4销售低于预期,阿尔兹海默症药物短期内难创收
加载更多
公司概况
公司名称:
渤健公司
所属市场:
NASDAQ
上市日期:
--
主营业务:
Biogen Inc.于1985年在加利福尼亚州以IDEC制药公司的名义成立,并于1997年重新注册为特拉华州公司。2003年,他们收购了Biogen, Inc.,并将公司名称更改为Biogen Idec Inc.。该公司是一家全球性的生物制药公司,专注于为患有严重神经和神经退行性疾病的患者以及相关的治疗邻接患者发现、开发和提供全球创新疗法。该公司的核心增长领域包括多发性硬化症(MS)和神经免疫学;阿尔茨海默病(AD)和痴呆症;神经肌肉疾病,包括脊髓肌萎缩症(SMA)和肌萎缩侧索硬化症(ALS);运动障碍,包括帕金森氏症;以及眼科学。该公司还专注于在免疫学、神经认知障碍、急性神经学和疼痛等新兴增长领域发现、开发和提供全球创新疗法。
发行价格:
--
{"stockData":{"symbol":"BIIB","market":"US","secType":"STK","nameCN":"渤健公司","latestPrice":190.52,"timestamp":1713470400000,"preClose":192.16,"halted":0,"volume":1512005,"hourTrading":{"tag":"盘后","latestPrice":190.52,"preClose":190.52,"latestTime":"19:59 EDT","volume":33478,"amount":6378548.14,"timestamp":1713484755151},"delay":0,"floatShares":144815069,"shares":145360798,"eps":7.97,"marketStatus":"未开盘","marketStatusCode":0,"change":-1.64,"latestTime":"04-18 16:00:00 EDT","open":191.75,"high":192.56,"low":189.52,"amount":288605919.98149997,"amplitude":0.01582,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":7.97,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1713513600000},"adr":0,"listingDate":685080000000,"adjPreClose":192.16,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":191.96,"preClose":192.16,"latestTime":"09:29 EDT","volume":560,"amount":107456.5128,"timestamp":1713446999999},"postHourTrading":{"tag":"盘后","latestPrice":190.52,"preClose":190.52,"latestTime":"19:59 EDT","volume":33478,"amount":6378548.14,"timestamp":1713484755151},"volumeRatio":1.34594},"requestUrl":"/m/hq/s/BIIB","defaultTab":"news","newsList":[{"id":"2426257723","title":"小摩:维持Biogen(BIIB.US)评级,由中性调整至中性评级, 目标价由270.00美元调整至240.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2426257723","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426257723?lang=zh_cn&edition=full","pubTime":"2024-04-11 20:55","pubTimestamp":1712840125,"startTime":"0","endTime":"0","summary":"小摩:维持Biogen(BIIB.US)评级,由中性调整至中性评级, 目标价由270.00美元调整至240.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404112055288b106616&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404112055288b106616&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426284371","title":"美国研究综述-Airbnb、Albemarle、Biogen","url":"https://stock-news.laohu8.com/highlight/detail?id=2426284371","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2426284371?lang=zh_cn&edition=full","pubTime":"2024-04-11 15:32","pubTimestamp":1712820730,"startTime":"0","endTime":"0","summary":" 路透社4月11日 - 华尔街证券分析师周四调整了对几家美国上市公司的评级和目标价,其中包括 Airbnb、Albemarle 和 Biogen。* Aflac Inc :杰富瑞将目标价从 83 美元上调至 84 美元 * Airbnb Inc :Benchmark给予买入评级,目标价190美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":1},{"id":"2424079470","title":"BUZZ-百健因阿尔茨海默氏症皮下注射药物Leqembi申请延迟而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2424079470","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2424079470?lang=zh_cn&edition=full","pubTime":"2024-04-01 18:59","pubTimestamp":1711969146,"startTime":"0","endTime":"0","summary":" 4月1日 - ** 百健 股价盘前下跌1.25%至212.94美元** 该公司的合作伙伴卫材 表示, ,阿尔茨海默氏症药物Leqembi的皮下注射形式的 监管申请被推迟。** 卫材的目标是在上个月提交皮下注射每周维持疗法的上市申请。** 卫材原计划在 FDA 快速通道指定的滚动审查期间提供这些数据,但皮下注射制剂不具备这一条件。** Leqembi 的静脉注射剂型去年获得了 FDA 的标准批准 ** 截至上日收盘,BIIB股价年累计下跌约17%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2421575896","title":"更新版 1-欧盟药品监管机构未在会议记录中提及卫材-百健的阿尔茨海默氏症药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2421575896","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2421575896?lang=zh_cn&edition=full","pubTime":"2024-03-22 19:05","pubTimestamp":1711105550,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) (添加背景信息) 路透社3月22日 - 欧盟药品监管机构周五在其说明和建议中没有提及卫材 和百健 的阿尔茨海默氏症药物。 欧洲药品管理局曾表示将在本周举行口头听证会,讨论这种名为lecanemab的药物。 该药在美国以Leqembi的名义销售,自2023年1月起在欧洲接受审查。该药去年在美国获得传统批准,并在中国和日本等其他国家获得批准。 这种药物每月输注两次,可以清除大脑中被认为是阿尔茨海默氏症标志的淀粉样β蛋白的粘性团块。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2418061964","title":"BUZZ-美国食品及药物管理局推迟阿尔茨海默氏症药物决策后,礼来公司股价下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2418061964","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2418061964?lang=zh_cn&edition=full","pubTime":"2024-03-09 00:25","pubTimestamp":1709915155,"startTime":"0","endTime":"0","summary":" (更新) 3月8日 - ** 制药商礼来 股价下跌1.3%至766.17美元** 该公司称, ,美国食品和药物管理局已推迟就其针对早期阿尔茨海默病患者的实验性治疗药物多那尼单抗做出决定,并将召开外部专家会议讨论该药物的安全性和有效性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2417374070","title":"BUZZ-礼来因美国食品及药物管理局推迟阿尔茨海默氏症药物决策而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2417374070","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2417374070?lang=zh_cn&edition=full","pubTime":"2024-03-08 19:59","pubTimestamp":1709899149,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 3月8日 - ** 制药商礼来 股价盘前下跌近1.2%,至771.06美元** 称 (link),美国食品和药物管理局(FDA)已推迟决定是否批准其针对早期阿尔茨海默病患者的实验性疗法多那尼单抗,并将召开外部专家会议讨论该疗法的安全性和有效性。** 称咨询委员会会议的日期尚未确定,但可能会在几个月后召开** Donanemab将与卫材 和百健公司<Biogen BIIB.O>的Leqembi竞争。** 百健公司股价在收盘前上涨了 3.7%,报 227 美元。** 截至上次收盘,LLY 的股价在过去 12 个月里上涨了一倍多","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2417032402","title":"美国 FDA 推迟礼来老年痴呆症药物决策,要求成立顾问小组","url":"https://stock-news.laohu8.com/highlight/detail?id=2417032402","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2417032402?lang=zh_cn&edition=full","pubTime":"2024-03-08 19:45","pubTimestamp":1709898304,"startTime":"0","endTime":"0","summary":"礼来公司表示,咨询委员会讨论该药的会议日期尚未确定,但可能要等几个月才能召开。怀特说,FDA 希望专家小组讨论在申请传统 FDA 批准时所采用的临床试验的一些独特之处,包括围绕疗效和安全性的问题。美国食品和药物管理局一年前决定不加速批准该公司的这种药物,这次意外的推迟是继该决定之后的又一决定。礼来公司的后期研究显示,24%的多那单抗治疗组患者出现了脑肿胀。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2417736604","title":"日本卫材公司称美国引进阿尔茨海默氏症药物Leqembi的速度低于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2417736604","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2417736604?lang=zh_cn&edition=full","pubTime":"2024-03-07 16:36","pubTimestamp":1709800583,"startTime":"0","endTime":"0","summary":" 路透社东京3月7日 - 日本制药商卫材 周四表示,其阿尔茨海默氏症药物Leqembi在美国的销售进度慢于预期。Leqembi 是一种抗体,旨在清除阿尔茨海默病患者大脑中一种名为淀粉样蛋白 beta 的粘性沉积物。它是第一种在阿尔茨海默氏症早期阶段用药就能延缓病情恶化的治疗方法。今年 1 月,中国监管机构批准了 Leqembi 的上市,卫材的目标是今年在中国上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2413567547","title":"欧盟药品监管机构支持百健公司的 ALS 药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2413567547","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2413567547?lang=zh_cn&edition=full","pubTime":"2024-02-23 18:56","pubTimestamp":1708685806,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 路透社2月23日 - 欧洲药品监管机构周五表示,已建议批准百健公司的 药物上市,用于治疗一种被称为肌萎缩性脊髓侧索硬化症的神经系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2412768667","title":"渤健公司2023财年实现净利润11.61亿美元,同比减少61.90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2412768667","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2412768667?lang=zh_cn&edition=full","pubTime":"2024-02-17 00:23","pubTimestamp":1708100587,"startTime":"0","endTime":"0","summary":"12月31日,渤健公司公布财报,公告显示公司2023财年净利润为11.61亿美元,同比减少61.90%;其中营业收入为94.17亿美元,同比减少0.17%,每股基本收益为8.02美元。从资产负债表来看,渤健公司总负债120.45亿美元,其中短期债务2.40亿美元,资产负债比为2.23,流动比率为2.00。机构评级:截至2023年12月31日,当前有26家机构对渤健公司目标价做出预测,其中目标均价为303.42美元,其中最低目标价为230.00美元,最高目标价为400.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240217002321879794ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240217002321879794ba&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2411294309","title":"BUZZ-Sage Therapeutics 因第四季度收入增长、亏损收窄而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2411294309","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411294309?lang=zh_cn&edition=full","pubTime":"2024-02-14 21:47","pubTimestamp":1707918463,"startTime":"0","endTime":"0","summary":" 2月14日 - ** 制药公司Sage Therapeutics 的股价盘前上涨2%,达到23.50美元。** ,超过预期的6098万美元。** 该公司第四季度每股亏损55美分,低于分析师预计的亏损1.28美元。** SAGE 公司称,12 月中旬推出的产后抑郁症药物 Zurzuvae 为公司带来了 80 万美元的季度合作收入。** 过去 12 个月股价下跌 48.7","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2411372218","title":"百健公司收到司法部传票,内容涉及在国外的业务运营情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2411372218","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411372218?lang=zh_cn&edition=full","pubTime":"2024-02-14 19:18","pubTimestamp":1707909504,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 路透社2月14日 - Biogen 在周三提交的一份文件中披露,该公司已收到美国司法部的传票,要求其提供与该公司在几个外国的业务运营有关的信息。该公司没有立即回应路透社的置评请求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2411322694","title":"美国研究综述-布鲁克公司、Cymabay Therapeutics、SSR 矿业公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2411322694","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411322694?lang=zh_cn&edition=full","pubTime":"2024-02-14 15:35","pubTimestamp":1707896137,"startTime":"0","endTime":"0","summary":" 路透社2月14日 - 华尔街证券分析师周三调整了对布鲁克公司、Cymabay Therapeutics 和 SSR 矿业公司等几家美国上市公司的评级和目标价。要点 * 布鲁克公司 :摩根大通将其评级从中性上调至增持 * Cymabay Therapeutics Inc :Piper Sandler将其评级从 \"增持 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2411341237","title":"《美股业绩》渤健药厂(BIIB.US)业绩预测逊预期 股价挫逾7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2411341237","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2411341237?lang=zh_cn&edition=full","pubTime":"2024-02-14 11:14","pubTimestamp":1707880440,"startTime":"0","endTime":"0","summary":"美国渤健药厂公布去年第四季业绩。纯利按年跌55%至2.5亿美元,每股季度摊薄纯利1.71美元,经调整后为2.95美元。公司去年同期录得1.95亿美元或有对价重估收益,现财年重组支出亦年增逾9,000万美元,但收购资产减值按年减少近1亿美元。公司季内收入按年跌6%至23.86亿美元,差于市场预期的24.7亿美元。公司预期今年经调整每股盈利介乎15至16美元,中位数低于市场预期的15.65美元。渤健股价昨日跌7.4%,报226.65美元。","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20231101162223664_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20231101162223664_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1326374/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2411839396","title":"嗡嗡声--美国股票走势-捷蓝航空公司、LPL Financial、Nvidia","url":"https://stock-news.laohu8.com/highlight/detail?id=2411839396","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411839396?lang=zh_cn&edition=full","pubTime":"2024-02-14 03:25","pubTimestamp":1707852333,"startTime":"0","endTime":"0","summary":" * Eikon 个股走势搜索字符串:[STXBZ] * The Day Ahead 新闻通讯: * The Morning News Call时事通讯: 2月13日 - 华尔街主要股指周二下滑,触及一周低点,此前消费者通胀数据高于预期,推动美国国债收益率走高,令市场对即将降息的猜测打消。美东时间13:36,道琼斯工业平均指数 报38,133.46点,上涨1.71%。标准普尔500指数 下跌1.36%,报4,953.74点;纳斯达克综合指数 下跌1.68%,报15,675.194点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2411393223","title":"BUZZ-利润和营收不及预期,百健公司技术面转为看跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2411393223","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411393223?lang=zh_cn&edition=full","pubTime":"2024-02-14 02:50","pubTimestamp":1707850231,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 2月13日 - ** 生物基因公司 创下11月底以来的最低水平,成交价为225.78美元** 由于第四季度利润和收入预期不及预期,从 1 月份高点回落的趋势得以延续 (link) ** 股价进一步跌离看跌排列的 10 和 30-DMAs** 日线相对强弱指数(RSI) 暗示仍有下跌动能** 突破 220.86 美元至 268.27 美元升势的 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2411708369","title":"BUZZ-第四季度利润和收入不及预期,百健公司下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2411708369","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411708369?lang=zh_cn&edition=full","pubTime":"2024-02-14 00:01","pubTimestamp":1707840115,"startTime":"0","endTime":"0","summary":" (更新) 2月13日 - ** 百健 股价下跌7.2%,至227.27美元 ** 如果跌势持续,股价将创两年多来最大单日跌幅 ** 该公司公布的 第四季度利润和收入低于 华尔街预期 * * 受 多发性硬化症药物 Tecfidera 销售 疲软的影响,季度收入为 23.9 亿美元,低于预期的 24.7 亿美元 ** 第四季度每股收益为 2.95 美元,低于预期的 3.18 美元--LSEG 数据** 该公司第四季度利润减少35美分,原因是决定归还阿尔茨海默病药物Aduhelm的销售权 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2411354080","title":"百健Q4销售低于预期,阿尔兹海默症药物短期内难创收","url":"https://stock-news.laohu8.com/highlight/detail?id=2411354080","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2411354080?lang=zh_cn&edition=full","pubTime":"2024-02-13 22:12","pubTimestamp":1707833551,"startTime":"0","endTime":"0","summary":"财报显示,因为该公司的多发性硬化症药物持续下滑,百健Q4营收24亿美元,同比降低5.5%,低于平均预期的 24.6 亿美元;非公认会计准则下每股收益为2.95美元,不及市场预期;上年同期为4.05美元。这是首个被批准的治疗弗里德赖希共济失调的药物。百健本周宣布,Skyclarys也已在欧洲获得批准。该公司表示,其收益受到每股35美分的负面影响,这与该公司最近决定停止研究和销售有争议的阿尔茨海默病药物Aduhelm有关。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1071701.html","is_publish_highlight":true,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.biogen.com","stockEarnings":[{"period":"1week","weight":-0.0646},{"period":"1month","weight":-0.1286},{"period":"3month","weight":-0.2378},{"period":"6month","weight":-0.26},{"period":"1year","weight":-0.3481},{"period":"ytd","weight":-0.2637}],"compareEarnings":[{"period":"1week","weight":-0.0357},{"period":"1month","weight":-0.0314},{"period":"3month","weight":0.0354},{"period":"6month","weight":0.186},{"period":"1year","weight":0.2062},{"period":"ytd","weight":0.0509}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Biogen Inc.于1985年在加利福尼亚州以IDEC制药公司的名义成立,并于1997年重新注册为特拉华州公司。2003年,他们收购了Biogen, Inc.,并将公司名称更改为Biogen Idec Inc.。该公司是一家全球性的生物制药公司,专注于为患有严重神经和神经退行性疾病的患者以及相关的治疗邻接患者发现、开发和提供全球创新疗法。该公司的核心增长领域包括多发性硬化症(MS)和神经免疫学;阿尔茨海默病(AD)和痴呆症;神经肌肉疾病,包括脊髓肌萎缩症(SMA)和肌萎缩侧索硬化症(ALS);运动障碍,包括帕金森氏症;以及眼科学。该公司还专注于在免疫学、神经认知障碍、急性神经学和疼痛等新兴增长领域发现、开发和提供全球创新疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.575758,"avgChangeRate":0.042714},{"month":2,"riseRate":0.424242,"avgChangeRate":-0.004267},{"month":3,"riseRate":0.515152,"avgChangeRate":-0.023197},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.021759},{"month":5,"riseRate":0.59375,"avgChangeRate":0.031756},{"month":6,"riseRate":0.46875,"avgChangeRate":0.017689},{"month":7,"riseRate":0.6875,"avgChangeRate":0.038795},{"month":8,"riseRate":0.59375,"avgChangeRate":0.032796},{"month":9,"riseRate":0.5,"avgChangeRate":0.024456},{"month":10,"riseRate":0.545455,"avgChangeRate":0.062497},{"month":11,"riseRate":0.606061,"avgChangeRate":0.016153},{"month":12,"riseRate":0.484848,"avgChangeRate":0.038726}],"exchange":"NASDAQ","name":"渤健公司","nameEN":"Biogen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供渤健公司(BIIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"渤健公司,BIIB,渤健公司股票,渤健公司股票老虎,渤健公司股票老虎国际,渤健公司行情,渤健公司股票行情,渤健公司股价,渤健公司股市,渤健公司股票价格,渤健公司股票交易,渤健公司股票购买,渤健公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供渤健公司(BIIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}